AR082223A1 - Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodo - Google Patents
Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodoInfo
- Publication number
- AR082223A1 AR082223A1 ARP110102545A ARP110102545A AR082223A1 AR 082223 A1 AR082223 A1 AR 082223A1 AR P110102545 A ARP110102545 A AR P110102545A AR P110102545 A ARP110102545 A AR P110102545A AR 082223 A1 AR082223 A1 AR 082223A1
- Authority
- AR
- Argentina
- Prior art keywords
- conjugate
- hgh
- human
- region
- human growth
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 8
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 8
- 239000000854 Human Growth Hormone Substances 0.000 abstract 8
- 108060003951 Immunoglobulin Proteins 0.000 abstract 3
- 102000018358 immunoglobulin Human genes 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100067796A KR101337797B1 (ko) | 2010-07-14 | 2010-07-14 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082223A1 true AR082223A1 (es) | 2012-11-21 |
Family
ID=45469941
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102545A AR082223A1 (es) | 2010-07-14 | 2011-07-14 | Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodo |
| ARP180100643A AR113034A2 (es) | 2010-07-14 | 2018-03-20 | Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100643A AR113034A2 (es) | 2010-07-14 | 2018-03-20 | Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9061072B2 (enExample) |
| EP (1) | EP2593084B1 (enExample) |
| JP (1) | JP5946448B2 (enExample) |
| KR (1) | KR101337797B1 (enExample) |
| AR (2) | AR082223A1 (enExample) |
| AU (1) | AU2011277203B2 (enExample) |
| BR (1) | BR112013000902A2 (enExample) |
| CA (1) | CA2805228C (enExample) |
| ES (1) | ES2673022T3 (enExample) |
| IL (1) | IL224225B (enExample) |
| RU (1) | RU2623026C2 (enExample) |
| TW (1) | TWI459961B (enExample) |
| WO (1) | WO2012008779A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI601744B (zh) | 2011-06-17 | 2017-10-11 | 韓美科學股份有限公司 | 包含調酸素與免疫球蛋白片段之複合物及其用途 |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| US10064951B2 (en) * | 2012-03-30 | 2018-09-04 | Hanmi Science Co., Ltd. | Liquid formulation of highly concentrated long-acting human growth hormone conjugate |
| AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| EA039082B1 (ru) | 2012-11-06 | 2021-12-01 | Ханми Фарм. Ко., Лтд. | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина |
| JP2016511275A (ja) | 2013-03-11 | 2016-04-14 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 成長ホルモン化合物 |
| SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| AR096890A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
| CN105848645A (zh) | 2013-09-27 | 2016-08-10 | 韩美药品株式会社 | 持续型人生长激素制剂 |
| KR102385120B1 (ko) * | 2014-03-31 | 2022-04-12 | 한미약품 주식회사 | 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법 |
| TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| KR102527180B1 (ko) | 2014-12-10 | 2023-04-27 | 옵코 바이오로직스 리미티드 | 장기간 작용성 ctp-변형된 성장 호르몬 폴리펩타이드의 제조 방법 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| US9375478B1 (en) * | 2015-01-30 | 2016-06-28 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| EP3303380B1 (en) | 2015-06-02 | 2020-01-15 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
| DK3347403T3 (da) | 2015-09-11 | 2020-06-29 | Dow Global Technologies Llc | Polyalkoxyfedtforbindelse |
| DK3347031T3 (da) | 2015-09-11 | 2021-04-26 | Nutrition & Biosciences Usa 1 Llc | Sammensætning, der omfatter et protein og en polyalkoxyfedtforbindelse |
| JP2018535929A (ja) * | 2015-09-24 | 2018-12-06 | バイオマリン ファーマシューティカル インコーポレイテッド | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
| WO2017055582A1 (en) | 2015-10-01 | 2017-04-06 | Novo Nordisk A/S | Protein conjugates |
| KR20170079409A (ko) * | 2015-12-30 | 2017-07-10 | 한미약품 주식회사 | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 |
| JP2020513019A (ja) | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー／エス | オリゴマー伸長インスリン−Ｆｃコンジュゲート |
| JP7604174B2 (ja) * | 2019-10-30 | 2024-12-23 | Ｊｃｒファーマ株式会社 | 血清アルブミンと成長ホルモンの融合蛋白質を含有する水性医薬組成物 |
| US12196531B2 (en) | 2020-07-17 | 2025-01-14 | ProtectEd Solutions LLC | Protective cabinet |
| MX2024006318A (es) * | 2021-11-26 | 2024-08-14 | Genexine Inc | Formulacion para administracion de alta concentracion de proteina de fusion de hormona del crecimiento. |
| EP4640210A1 (en) * | 2022-12-23 | 2025-10-29 | Hanmi Pharm. Co., Ltd. | Formulation containing immunoactive interleukin 2 analog conjugate |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981485A (en) * | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
| SE9201073D0 (sv) * | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
| DK0955062T3 (da) * | 1992-07-31 | 2007-09-17 | Genentech Inc | Vandig formulering indeholdende humant væksthormon |
| US5519253A (en) * | 1993-09-07 | 1996-05-21 | Delco Electronics Corp. | Coaxial switch module |
| US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| JP3723857B2 (ja) | 1998-02-04 | 2005-12-07 | 日本ケミカルリサーチ株式会社 | ヒト成長ホルモン含有水性医薬組成物 |
| ATE407697T1 (de) * | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| GB2371227A (en) * | 2001-01-10 | 2002-07-24 | Grandis Biotech Gmbh | Crystallisation - resistant aqueous growth hormone formulations |
| US20060183197A1 (en) * | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
| US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| KR100537260B1 (ko) | 2003-09-03 | 2005-12-19 | 한미약품 주식회사 | 인간 성장 호르몬의 안정화된 액상 제제용 조성물 |
| BRPI0406605B8 (pt) | 2003-11-13 | 2021-05-25 | Hanmi Holdings Co Ltd | conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo |
| JP4845741B2 (ja) | 2003-12-23 | 2011-12-28 | ファルマシア コーポレーション | 安定な成長ホルモン液体製剤 |
| WO2006048689A2 (en) * | 2004-11-08 | 2006-05-11 | Encesys Limited | Integrated circuits and power supplies |
| KR100754667B1 (ko) * | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| KR100739728B1 (ko) * | 2005-09-01 | 2007-07-13 | 삼성전자주식회사 | 화상형성시스템 및 화상 형성 방법 |
| US8400775B2 (en) * | 2007-07-06 | 2013-03-19 | GM Global Technology Operations LLC | Capacitor with direct DC connection to substrate |
| EP2300501B1 (en) * | 2008-07-23 | 2014-08-20 | Hanmi Science Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
| MX2011005672A (es) | 2008-11-28 | 2011-06-20 | Abbott Lab | Composiciones de anticuerpo estables y metodos para estabilizar a las mismas. |
-
2010
- 2010-07-14 KR KR1020100067796A patent/KR101337797B1/ko not_active Expired - Fee Related
-
2011
- 2011-07-14 TW TW100125060A patent/TWI459961B/zh not_active IP Right Cessation
- 2011-07-14 US US13/809,783 patent/US9061072B2/en not_active Expired - Fee Related
- 2011-07-14 AR ARP110102545A patent/AR082223A1/es not_active Application Discontinuation
- 2011-07-14 WO PCT/KR2011/005194 patent/WO2012008779A2/en not_active Ceased
- 2011-07-14 EP EP11807064.8A patent/EP2593084B1/en not_active Not-in-force
- 2011-07-14 BR BR112013000902-0A patent/BR112013000902A2/pt not_active IP Right Cessation
- 2011-07-14 RU RU2013106276A patent/RU2623026C2/ru not_active IP Right Cessation
- 2011-07-14 JP JP2013519600A patent/JP5946448B2/ja not_active Expired - Fee Related
- 2011-07-14 AU AU2011277203A patent/AU2011277203B2/en not_active Ceased
- 2011-07-14 ES ES11807064.8T patent/ES2673022T3/es active Active
- 2011-07-14 CA CA2805228A patent/CA2805228C/en not_active Expired - Fee Related
-
2013
- 2013-01-14 IL IL224225A patent/IL224225B/en active IP Right Grant
-
2018
- 2018-03-20 AR ARP180100643A patent/AR113034A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101337797B1 (ko) | 2013-12-06 |
| RU2013106276A (ru) | 2014-08-20 |
| CN103068366A (zh) | 2013-04-24 |
| ES2673022T3 (es) | 2018-06-19 |
| EP2593084B1 (en) | 2018-03-14 |
| AU2011277203A1 (en) | 2013-02-28 |
| AR113034A2 (es) | 2020-01-22 |
| RU2623026C2 (ru) | 2017-06-21 |
| US20130115231A1 (en) | 2013-05-09 |
| WO2012008779A3 (en) | 2012-05-24 |
| WO2012008779A2 (en) | 2012-01-19 |
| US9061072B2 (en) | 2015-06-23 |
| EP2593084A2 (en) | 2013-05-22 |
| JP5946448B2 (ja) | 2016-07-06 |
| TWI459961B (zh) | 2014-11-11 |
| BR112013000902A2 (pt) | 2020-08-25 |
| TW201215404A (en) | 2012-04-16 |
| JP2013531034A (ja) | 2013-08-01 |
| AU2011277203B2 (en) | 2015-11-12 |
| IL224225B (en) | 2018-07-31 |
| CA2805228A1 (en) | 2012-01-19 |
| CA2805228C (en) | 2019-05-07 |
| EP2593084A4 (en) | 2014-11-05 |
| KR20120007182A (ko) | 2012-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121939A2 (es) | Composición líquida de un conjugado derivado de oxintomodulina de larga duración y procedimiento para prepararla | |
| WO2012008779A3 (en) | A liquid formulation of long-acting human growth hormone conjugate | |
| MX369479B (es) | Formulación líquida de un cunjugado de péptido insulinotropico de acción prolongada. | |
| AR091902A1 (es) | Formulacion liquida de un conjugado de insulina de accion prolongada | |
| MX358647B (es) | Formulacion liquida de insulina de accion prolongada y de peptido insulinotropico. | |
| AR095451A1 (es) | Formulación de anticuerpos | |
| MX349441B (es) | Formulaciones liquidas de un conjugado de alfa interferon de accion prolongada. | |
| EA201691297A1 (ru) | Среда для культивирования клеток | |
| PE20140795A1 (es) | Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada | |
| RU2014140137A (ru) | Лекарственный препарат антитела к бета-амилоиду | |
| EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
| DOP2009000222A (es) | Formulaciones estables de anticuerpo | |
| AR077454A1 (es) | Preparaciones insulinicas que comprenden metionina | |
| WO2012018638A3 (en) | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures | |
| UA113172C2 (uk) | Стійкий рідкий препарат етанерцепту | |
| BR112013026883A2 (pt) | Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica | |
| UY33515A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ngf | |
| HRP20221139T1 (hr) | Stabilizirane formulacije koje sadrže antitijela protiv interleukin-6 receptora (il-6r) | |
| NZ609469A (en) | Improved high concentration anti-tnfα antibody liquid formulations | |
| PH12015501931A1 (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| AR089231A1 (es) | Metodo de floculacion | |
| AR091155A1 (es) | Composicion farmaceutica acuosa que contiene un agente terapeutico biologico y guanidina o un derivado de guanidina y una inyeccion que incluye la composicion | |
| AR097840A1 (es) | Una formulación de un conjugado de la hormona de crecimiento humana de la actividad prolongada, procedimiento, kit | |
| MX2014004132A (es) | Señuelos humanos notch1. | |
| AR107276A1 (es) | Una formulación líquida de conjugado de hormona del crecimiento humana de acción prolongada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |